

## GENERAL MEETING OF APRIL 28, 2020

### WRITTEN QUESTION

Written questions may be submitted to the Company, pursuant to the rules established by law, with respect to any General Meeting. In accordance with the legislation in force, an answer is deemed to have been given to a written question provided it has been displayed on the Company's website.

On April 6, 2020 the Board received the question below from Mrs. AM Moncelle, member of the Comité de Consultation des Actionnaires individuels (CCA):

Can you please explain why Sanofi has been indicted in the Depakine case?

Reply:

In addition to proceedings initiated against the French affiliate Sanofi Aventis France before the civil courts and against the Health Authority before administrative courts in respect of Depakine, the APESAC (a French patient association "Association d'Aide aux Parents d'Enfants Souffrant du Syndrome de l'Anti-Convulsivant") and several families had filed a criminal complaint against person unknown ("plainte contre X") before the Public Prosecutor in 2016. Within the frame of this criminal investigation, Sanofi Aventis France – formerly under the status of "assisted witness" in this investigation - has now been indicted for aggravated deceit and involuntary harm. With this change of status, the affiliate company becomes a party to the investigation.

The indictment allows Sanofi Aventis France to fully exercise its rights of defense, which it could not do under its former status of assisted witness. This will be an opportunity for the company to demonstrate compliance with its obligation to inform and reiterate that it has observed transparency.

It is worth mentioning that an indictment does not in any way imply that some liabilities have been determined. Neither does it mean that Sanofi Aventis France will be referred to the criminal jurisdiction or even that a trial could take place.

Sanofi will continue to cooperate fully with the judicial authorities within this investigation.

\*\*\*